> ## Content Index
> Fetch the complete content index at: https://www.alwihdainfo.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
- URL: https://www.alwihdainfo.com/boehringer-ingelheim-and-lilly-announce-clinical-trial-collaboration-in-metastatic-breast-cancer-a37067/
- Published: 2016-07-13T13:00:00.000Z
- Updated: 2026-04-02T13:56:40.000Z
- Author: Alwihda Info
- Tags: ACTUALITES, #Import 2026-04-02 13:55

**• *Study to evaluate potential of novel combination therapy for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC)***

***•* *Boehringer Ingelheim's IGF mAB BI 836845 and Lilly's CDK 4 and 6 inhibitor abemaciclib have shown promising early phase results in metastatic breast cancer***

([BUSINESS WIRE](http://www.businesswire.com/?ref=alwihdainfo.com))-- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralising antibody, in combination with abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, in patients diagnosed with HR+/HER2- mBC. ...  
  
Source : [http://me-newswire.net//news/18332/en...](http://me-newswire.net//news/18332/en?ref=alwihdainfo.com)